MedTrace Logo

Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis

NCT03593590 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1710

Last updated 2026-02-17

No results posted yet for this study

Summary

This is a multicentre non-interventional study aimed at evaluating the real-world effectiveness and safety of ocrelizumab treatment in participants with relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS), who have been prescribed ocrelizumab as per routine practice. This study will use a comprehensive combination of participant reported outcomes and conventional multiple sclerosis (MS) endpoints that measure clinical domains commonly affected by MS (e.g. fatigue, hand function, gait, cognition), and their impact on employment, activities of daily living, quality of life and healthcare resource utilization. The incidence, type, and pattern of serious adverse events (SAEs), and of adverse events (AEs) leading to treatment discontinuation will also be determined.

Conditions

Interventions

DRUG

Ocrelizumab

Ocrelizumab is administered as an intravenous infusion in accordance with the approved labelling.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-12
Primary Completion
2026-01-19
Completion
2026-01-19

Countries

  • Austria
  • Belgium
  • Brazil
  • Bulgaria
  • Chile
  • Colombia
  • Dominican Republic
  • Egypt
  • Italy
  • Kuwait
  • Montenegro
  • Netherlands
  • Paraguay
  • Poland
  • Portugal
  • Qatar
  • Romania
  • Russia
  • Saudi Arabia
  • Serbia
  • Slovakia
  • Spain
  • Turkey (Türkiye)
  • United Arab Emirates
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03593590 on ClinicalTrials.gov